What bear market? Blueprint lines up $1.25B to expand labels, maybe tack on more drugs - Endpoints News
6/30/2022 12:00:00 AM3 years 8 months ago
by Kyle LaHucik
by Kyle LaHucik
As it works to pad the case for expanding its Ayvakit and Gavreto labels, Blueprint Medicines has lined up $1.25 billion in funding, with some of that money seemingly earmarked for acquisitions or pipeline expansion projects. Following the likes of BioCryst, …
A manufacturing facility belonging to the Netherlands-based API producer Fagron Group has entered the FDA’s crosshairs after an employee destroyed a cleaning log, among other violations. One of its … [+610 chars]
full article...